Technology and Patent Rights Clause Samples

Technology and Patent Rights. Except pursuant to a separate agreement, a Party purchasing an Instrument from the other Party will not get any right under the other Party’s Technology and Patent Rights directed to Instruments to make or have made such Instrument. [***] indicates material that has been omitted pursuant to a request for confidential treatment. The omitted material has been filed separately with the Securities and Exchange Commission.
View SourceView Similar (4)
Technology and Patent Rights. Representations, warranties, covenants
View SourceView Similar (3)
Technology and Patent Rights. 1 is hereby revised to read as follows:
View Source
Technology and Patent Rights. University shall own and manage the Technology and shall apply for, obtain, and enforce its Patent Rights as required to protect the Technology in consultation with the Optionee during the Option Period. The Optionee agrees to pay up to twenty thousand dollars (C$20,000) of University’s actual legal and filing costs arising from applying for or obtaining of Patent Rights during the term of the Option Agreement (“Patent Costs”), due within thirty (30) days from the date of being invoiced by the University.
View Source
Technology and Patent Rights. NOXSO will provide the technology and patent rights to RPL as specified in Article 7 of this Agreement.
View Source
Technology and Patent Rights. PURE shall be the sole and exclusive owner of all Intellectual Property Rights. Licensee hereby irrevocably quitclaims and/or forever assigns to PURE all right, title and interest in and to the Intellectual Property Rights whether now in existence or hereinafter arising as between PURE and Licensee, all right, title and interest in all discoveries and inventions derived from the use of the Intellectual Property Rights hereunder or the activities otherwise contemplated by this Agreement (or otherwise) shall be owned solely by PURE. Licensee hereby represents and warrants that all employees and others acting on its behalf in performing its obligations or exercising its rights hereunder shall be obligated under a binding written agreement to quitclaim and/or forever assign to PURE all discoveries and inventions derived from the use of the Intellectual Property Rights hereunder or the activities otherwise contemplated by this Agreement conceived by such employees or others. PURE shall, at its sole expense and in its unfettered discretion, prepare, file, prosecute and maintain Patent Rights and Pure Marks in the United States and the Territory. PURE shall have the sole right, at its expense and at its sole unfettered option, to enforce Patent Rights and Pure Marks, as well as to retain all proceeds therefrom. Notwithstanding anything to the contrary herein, Licensee stipulates it has no rights respecting the Intellectual Property Rights.
View Source
Technology and Patent Rights 
View SourceView Similar (2)

Related to Technology and Patent Rights

  • Patent Rights The State and the U. S. Department of Transportation shall have the royalty free, nonexclusive and irrevocable right to use and to authorize others to use any patents developed by the Engineer under this contract.

  • Licensed Patent Rights The Licensee shall indemnify and hold the IC, its employees, students, fellows, agents, and consultants harmless from and against all liability, demands, damages, expenses, and losses, including but not limited to death, personal injury, illness, or property damage in connection with or arising out of:

  • Licensed Patents Immune Design, at its expense, shall have the first right to file, prosecute and maintain all Licensed Patents for which Immune Design has any exclusive rights under this Agreement using patent counsel reasonably approved by IDRI, including conducting any interferences, reexaminations, reissues, oppositions, or request for patent term extension relating thereto. Immune Design shall conduct such filing, prosecution and maintenance in good faith, taking into consideration IDRI’s retained rights hereunder, and consistent with reasonable business judgment, provide IDRI with all relevant or material documentation and proposed filing in the Territory so that IDRI may be concurrently and promptly informed of the continuing prosecution, and consult with IDRI with regards to Immune Design’s patent strategy with the Licensed Patents for which Immune Design has any exclusive rights under this Agreement. Licensed Patents in the name of IDRI shall remain in the name of IDRI. Immune Design shall use commercially reasonable efforts to ***, as applicable. To the extent such ***, Immune Design shall provide IDRI reasonable opportunity to review and comment on such prosecution efforts regarding such Licensed Patents in the Territory, and any IDRI comments will be reasonably considered in such prosecution efforts, and included to the extent affecting the IDRI Exclusive Field or IDRI Territory, as the case may be. If Immune Design determines in its sole discretion to abandon or not maintain any Licensed Patent for which Immune Design has any exclusive rights under this Agreement in the Territory, then Immune Design shall promptly provide IDRI with written notice of such determination at least sixty (60) days before any deadline for taking action to avoid abandonment and shall provide IDRI with the right, opportunity and reasonable assistance to prepare, file, prosecute and maintain such Licensed Patent in the applicable jurisdiction in IDRI’s sole discretion and at IDRI’s expense, provided that Immune Design shall provide such reasonable assistance at its own costs and expenses. If IDRI elects to prepare, file, prosecute and maintain such Licensed Patent in such jurisdiction for which Immune Design has any exclusive rights, then Immune Design’s license rights to such Licensed Patent in such country will become nonexclusive in such country under such Licensed Patent (and/or patent application). If IDRI desires Immune Design to file, in a particular jurisdiction, a Licensed Patent for which Immune Design has any exclusive rights under this Agreement that claims priority to another Licensed Patent for which Immune Design has any exclusive rights under this Agreement, IDRI shall provide written notice to Immune Design requesting that Immune Design file such patent application in such jurisdiction. If IDRI provides such written notice to Immune Design, Immune Design shall either (i) file and prosecute such patent application and maintain any patent issuing thereon in such jurisdiction and the Parties shall share the related costs and expenses (A) in countries *** on the basis of *** percent (***%) Immune Design: *** percent (***%) IDRI or (B) in countries within the IDRI Territory equally; or (ii) notify IDRI that Immune Design does not desire to file such patent application in such jurisdiction and provide IDRI with the opportunity to file and prosecute such patent application, provided that if IDRI files and prosecutes such patent application in such jurisdiction, then Immune Design’s license rights to such License Patent in such country will become nonexclusive in such country under such Licensed GLA Patent (and/or patent application). Immune Design shall be responsible for the costs and expenses incurred in connection with its own activities for filing, prosecuting and maintaining the Licensed Patents; IDRI shall be responsible for monitoring of such activities by IDRI.

  • INTELLECTUAL PROPERTY RIGHTS - INVENTION AND PATENT RIGHTS A. General 1. NASA has determined that 51 U.S.C. § 20135(b) does not apply to this Agreement. Therefore, title to inventions made (conceived or first actually reduced to practice) under this Agreement remain with the respective inventing party(ies). No invention or patent rights are exchanged or granted under this Agreement, except as provided herein.

  • Patents and Patent Applications To the Company’s knowledge, all patents and patent applications owned by or licensed to the Company or under which the Company has rights have been duly and properly filed and maintained; to the knowledge of the Company, the parties prosecuting such applications have complied with their duty of candor and disclosure to the USPTO in connection with such applications; and the Company is not aware of any facts required to be disclosed to the USPTO that were not disclosed to the USPTO and which could reasonably be expected to preclude the grant of a patent in connection with any such application or could reasonably be expected to form the basis of a finding of invalidity with respect to any patents that have issued with respect to such applications.